Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-10-07 DOI:10.1002/trc2.70157

Ataru Igarashi, Noriyuki Kimura, Takuya Ataka, Temmei Ito, Kotaro Sasaki, Chizuru Kobayashi, Mayaka Tani, Yukinori Sakata, Mie Azuma, Ayano Chida, Tomomi Takeshima, Kosuke Iwasaki, Etsuro Matsubara

{"title":"Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan","authors":"Ataru Igarashi, Noriyuki Kimura, Takuya Ataka, Temmei Ito, Kotaro Sasaki, Chizuru Kobayashi, Mayaka Tani, Yukinori Sakata, Mie Azuma, Ayano Chida, Tomomi Takeshima, Kosuke Iwasaki, Etsuro Matsubara","doi":"10.1002/trc2.70157","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment-eligible patients.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM-based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>A dynamic simulation models Alzheimer's diagnostic workflows in Japan.</li>\n \n <li>Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.</li>\n \n <li>Implementing BBM tests improves access to Alzheimer's diagnostics.</li>\n \n <li>Study quantifies demand for diagnostic testing based on costs and accessibility.</li>\n \n <li>Testing costs impact the number of treatment-eligible Alzheimer's patients.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 4","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70157","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

This study projected the diagnostic testing landscape for lecanemab treatment in Japan under different workflows.

METHODS

A dynamic simulation estimated wait times and treatment-eligible patient numbers under four scenarios: current diagnostic workflow, blood biomarker (BBM) tests as triage tools, BBM tests for confirmatory diagnostics, and both combined. Willingness-to-pay (WTP) and intangible costs were assessed via an online survey to estimate testing demand.

RESULTS

The maximum mean wait time under the current workflow was projected at 6.4 months, decreasing with BBM integration. The number of treatment-eligible patients increased considerably with BBM-based confirmatory diagnostics. BBM triage testing reduced wait times but temporarily increased treatment-eligible patients.

DISCUSSION

Replacing positron emission tomography (PET) or cerebrospinal fluid with BBM-based diagnostics may increase treatment eligibility because of lower costs, driving higher demand for testing.

Highlights

A dynamic simulation models Alzheimer's diagnostic workflows in Japan.
Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.
Implementing BBM tests improves access to Alzheimer's diagnostics.
Study quantifies demand for diagnostic testing based on costs and accessibility.
Testing costs impact the number of treatment-eligible Alzheimer's patients.

Abstract Image

查看原文本刊更多论文

在日本用血液生物标志物测试选项模拟阿尔茨海默病的诊断流程

本研究预测了日本在不同工作流程下莱卡耐单抗治疗的诊断测试前景。方法动态模拟估计了四种情况下的等待时间和符合治疗条件的患者人数：当前诊断工作流程，血液生物标志物（BBM）检测作为分诊工具，BBM检测用于确诊诊断，以及两者结合。通过在线调查评估支付意愿（WTP）和无形成本，以估计测试需求。结果当前工作流程下的最长平均等待时间预计为6.4个月，随着BBM的整合而减少。通过基于bbm的确诊诊断，符合治疗条件的患者数量显著增加。BBM分诊测试减少了等待时间，但暂时增加了符合治疗条件的患者。用基于bbm的诊断取代正电子发射断层扫描（PET）或脑脊液可能会增加治疗资格，因为成本更低，从而推动更高的检测需求。一个动态模拟模型在日本的阿尔茨海默病诊断工作流程。在日本，血液生物标志物（BBM）测试减少了阿尔茨海默氏症的诊断等待时间。实施BBM测试改善了阿尔茨海默病诊断的可及性。研究量化了基于成本和可及性的诊断测试需求。检测费用影响了符合治疗条件的阿尔茨海默病患者的数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.